Ketoconazole, a new broad-spectrum oral antifungal agent, has proved most useful in the treatment of superficial and systemic fungal infections. Chronic conditions like mucocutaneous candidiasis can be treated with but few side effects. An increasing number of cases have, however, been noted of severe toxic hepatitis, following ketoconazole treatment. A new case (a 61-yr-old woman treated for onychomycosis) is reported here. A. Swdhem, MD, Klin. Bakt. Institutionen, Guldhedsgat. 10, S-41346 Goteborg, Swcden Ketoconazole is a new oral synthetic imidazole-piperazine compound with broad antimycotic properties. It is still not registered in Sweden, being mainly used in the treatment of fungal skin disorders caused by Candida, and it has proved most effective in cases of chronic mucocutaneous candidiasis and onychomycosis, for which there was previously no remedy (2, 7). Although the side effects of ketoconazole have been few, and in most cases harmless, cases of severe toxic hepatitis are now being reported more frequently. By mid March 1982, 25 cases of icteric, and 6 of anicteric reactions had been reported (4), though causes other than ketoconazole could not be ruled out in all of these cases. A further case of severe icteric reaction to ketoconazole treatment is described here.